Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can acupuncture cool hot flashes in breast cancer survivors?

NCT ID NCT07294339

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether acupuncture can safely reduce hot flashes in women with hormone receptor-positive breast cancer who are on hormone therapy. Sixty patients will receive either real or sham acupuncture three times a week for eight weeks, then be followed for 16 more weeks. Researchers will also use brain scans to see how acupuncture might work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acupuncture
What this could lead to
If it works, this could offer a safe, non-drug option to reduce hot flashes for breast cancer patients on hormone therapy.
What could go wrong
This is a small, early-stage trial with only 60 participants, and the sham acupuncture group may also show benefits, making it hard to prove real effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Female patients aged 18 to 75 years. Histopathologically confirmed breast cancer, currently receiving endocrine therapy (e.g., selective estrogen receptor modulators and/or aromatase inhibitors, CDK4/6 inhibitors), with or without ovarian function suppression, for at least 4 weeks and ongoing at the time of enrollment. Expected survival time \> 6 months. Experiencing persistent hot flashes for at least 4 weeks, with a frequency of ≥14 episodes per week (≥2 per day) during the week prior to enrollment, and a Hot Flash Composite Score (HFCS) of 3-4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1: 0: Fully active, able to carry on all pre-disease performance without restriction; 1. Restricted in physically strenuous activity but ambulatory and able to carry out light work (e.g., housework, office work); 2. Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours; 3. Capable of only limited self-care; confined to bed or chair more than 50% of waking hours; 4. Completely disabled; cannot carry on any self-care; totally confined to bed or chair; 5. Dead. Willing and able to participate in the study and sign the informed consent form. Exclusion Criteria Evidence of tumor metastasis, currently undergoing radiotherapy, chemotherapy, or having a planned surgery. Use of selective serotonin reuptake inhibitors (SSRIs) and/or anticonvulsants or other pharmacologic agents for hot flash management within 4 weeks prior to study entry. Unstable cardiac disease or myocardial infarction within 6 months prior to study initiation. Recent initiation or modification of endocrine therapy within 1 week, or planned initiation or modification within 14 weeks. History or risk of seizure of unclear etiology. Prior acupuncture treatment for hot flashes within 6 months before enrollment. Contraindications to MRI scanning. Pregnant or lactating women. Presence of uncontrolled active infection. Severe psychiatric disorders or family history of psychiatric or neurological diseases. Withdrawal Criteria Failure to complete acupuncture treatment per protocol, making efficacy evaluation impossible. Use of medications or treatments during the trial that may affect study outcomes. Voluntary withdrawal from the study during treatment. Discontinuation Criteria Serious adverse events, complications, or physiological changes during treatment that make continuation unsafe or impractical. Loss to follow-up or death after enrollment. Participant's voluntary withdrawal at any stage of treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acupuncture treatment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    Beijing, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.